| 52.18 -1.49 (-2.78%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 64.69  |
1-year : | 69.76 |
| Resists | First : | 55.38 |
Second : | 59.72 |
| Pivot price | 51.38 |
|||
| Supports | First : | 48.36 | Second : | 40.23 |
| MAs | MA(5) : | 51.79  |
MA(20) : | 52.3 |
| MA(100) : | 48.69 |
MA(250) : | 31.89 |
|
| MACD | MACD : | -1 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 48.4 |
D(3) : | 41.3 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 66.37 | Low : | 14.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ETON ] has closed below upper band by 38.4%. Bollinger Bands are 41% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 53.66 - 53.93 | 53.93 - 54.1 |
| Low: | 51.24 - 51.6 | 51.6 - 51.83 |
| Close: | 51.67 - 52.21 | 52.21 - 52.55 |
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Fri, 30 Oct 2026
Eton Pharmaceuticals, Inc. (ETON) Seasonal returns chart - Yahoo Finance UK
Thu, 29 Oct 2026
Eton Pharmaceuticals, Inc. (ETON) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Thu, 29 Oct 2026
ETON Q3'26 Earnings: revenue estimate is 41.98M USD - TradingView
Thu, 29 Oct 2026
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 - The Manila Times
Thu, 29 Oct 2026
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 - GlobeNewswire
Thu, 29 Oct 2026
Investors can question Eton's management at its Nov. 5 results call. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 29 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 71.4 (%) |
| Shares Short | 1,830 (K) |
| Shares Short P.Month | 1,350 (K) |
| EPS | 0.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.64 |
| Profit Margin | 12 % |
| Operating Margin | 35.7 % |
| Return on Assets (ttm) | 11.8 % |
| Return on Equity (ttm) | 35.9 % |
| Qtrly Rev. Growth | 98.5 % |
| Gross Profit (p.s.) | 2.26 |
| Sales Per Share | 3.69 |
| EBITDA (p.s.) | 0.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 15 (M) |
| Levered Free Cash Flow | 7 (M) |
| PE Ratio | 130.44 |
| PEG Ratio | 0 |
| Price to Book value | 31.62 |
| Price to Sales | 14.12 |
| Price to Cash Flow | 98.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|